Evidence map›Paper›PMID 41550753›Full record

ArticleiScience2026

Accessible biocatalyst development by rapid

András Telek, Viktor Zsolt Gaják, Gergő Dargó, Jan Mičan, David Bednář, Beáta G Vértessy, Gábor Tasnádi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

András TelekDepartment of Applied Biotechnology and Food Science, Faculty of Chemical Technology and Biotechnology, Budapest University of Technology and Economics, Budapest 1111, Hungary.
Viktor Zsolt GajákServier Research Institute of Medicinal Chemistry, Budapest 1037, Hungary.
Gergő DargóServier Research Institute of Medicinal Chemistry, Budapest 1037, Hungary.
Jan MičanLoschmidt Laboratories, Department of Experimental Biology and RECETOX, Faculty of Science, Masaryk University, Brno 625 00, Czech Republic.
David BednářLoschmidt Laboratories, Department of Experimental Biology and RECETOX, Faculty of Science, Masaryk University, Brno 625 00, Czech Republic.
Beáta G VértessyDepartment of Applied Biotechnology and Food Science, Faculty of Chemical Technology and Biotechnology, Budapest University of Technology and Economics, Budapest 1111, Hungary.
Gábor TasnádiServier Research Institute of Medicinal Chemistry, Budapest 1037, Hungary.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tailoring natural enzymes to synthetic needs is often associated with high costs and long timelines, hindering the broader adoption of biocatalysis in the chemical and pharmaceutical industries. To address this, we developed the RISE (rapid

Indexed as

BiocatalysisBiotechnologyEnzyme engineering

Identifiers

PMID41550753
PMCPMC12804161

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.